Friday May 29, 2015 Search
Weather | Athens
14o C
09o C
News
Business
Comment
Life
Sports
Community
Survival Guide
Greek Edition
Drugmakers seek EU deal to keep supplies flowing

The head of Europe's drug industry has written to EU leaders ahead of their summit this week seeking major concessions to help keep supplies of medicines flowing to crisis-hit countries like Greece and Spain.

Faced with deep price cuts and billions of euros in unpaid bills, companies want two special measures to prevent discounts offered in southern Europe from being exported to rich states in the north, where governments can afford to pay for innovation.

In a forthright letter, GlaxoSmithKline Chief Executive Andrew Witty, who heads Europe's pharmaceuticals association, says failure to ring-fence austerity cuts will undermine a sector that provides 660,000 European jobs.

"In these extraordinary times for Europe, its economies and its citizens, business as usual - cost-containment policies that create market distortions - will drive investment elsewhere,» Witty said.

Reuters reviewed a copy of his letter sent to European Union leaders, Commission President Jose Manuel Barroso and Council President Herman Van Rompuy ahead of the June 28-29 summit.

The euro crisis has caught drugmakers between a rock and a hard place: they are under moral pressure to maintain supply to avert a health catastrophe, yet face financial losses.

The strain is starting to tell. Germany's Biotest, a small supplier of blood products, became the first drugmaker to pull out of Greece a week ago due to unpaid debts.

Greece's healthcare system is floundering under a tangle of unpaid bills. Industry figures show less than 1 percent of drug sales to the Greek state for the first quarter of 2012 have been paid off and the total is only 34 percent for the whole of 2011.

Big international drug companies have so far stuck with difficult markets such as Greece, although some like Roche and Novo Nordisk are demanding cash on delivery in certain cases. But Witty says they need support.

In Greece, Ireland, Italy, Portugal and Spain alone, drug companies have contributed more than 7 billion euros ($8.8 billion) to balancing health budgets through exceptional price cuts and discounts in 2010 and 2011, Witty wrote in his letter.

The overall impact is still greater because governments across Europe - and, indeed, across the world - refer to prices in southern Europe when setting their own drug prices.

Low prices in southern Europe have also helped suck medicines out of the region as wholesalers re-export drugs to countries, like Germany, where prices are higher.

To counter the problem, EU member states should agree to exclude from their reference pricing baskets any countries undergoing fiscal restructuring programs, according to the European Federation of Pharmaceutical Industries and Associations (Efpia), of which Witty is president.

Efpia also wants the EU to accept a temporary ban on the re-export of medicines from states that are fighting to rebalance public finances. This could help prevent supply shortages but it is a big ask, since the Commission closely guards the right to such free movement of goods under EU laws.

"We're asking the heads of state to help us, but by helping us they are also helping themselves,» Richard Bergstrom, the Brussels-based director general of Efpia, said in a telephone interview.

"That would unlock the potential for us to be more creative with governments in meeting their needs, particularly for those countries undergoing structural programs."

Witty's letter said Efpia firms had «worked very hard in the member states that have had the biggest challenges to try and ensure continuity of supply».

This includes weighing emergency plans to keep drugs flowing into Greece if it should crash out of the euro, industry sources said last month.

In return for such cooperation, drugmakers want a better return in richer countries. Executives from Pfizer, Bayer and GSK have all complained in recent months that Europe is undermining drug research by not paying its fair share relative to the United States and Japan.

There is particular frustration at drug vetting systems in countries like Germany and Britain, which often stop pricey medicines from being offered on state health systems.

Supporters of such cost-effectiveness regimes, however, say they are a counterbalance to profit-driven drug companies, which too often slap high prices on new products with few clinical advantages.

[Reuters]

ekathimerini.com , Monday June 25, 2012 (13:56)  
Greece, creditors seek breakthrough as clock runs down
Coast Guard officials linked to migrant traffickers
Civil aviation union cancels action on minister’s pledge
4.2-magnitude quake strikes off Crete
Greek credit contraction amounted to 2.4 pct in April
Credit expansion remained in negative territory last month as it contracted by 2.4 percent in April, according to data released on Friday by the Bank of Greece. In March the decline had come...
Export-oriented firms benefit from euro rate
The favorable shift in the exchange rate of the euro against the US dollar has led to the creation of two categories among Greek listed companies, as those who export their products to dolla...
Inside Business
SOCCER
Wemmer pens three-year deal with Panathinaikos
German defender Jens Wemmer has signed a three-year contract for an undisclosed sum with Panathinaikos, the Greek Super League club announced on Friday. Right-back Wemmer, 29, has been playi...
SOCCER
Panathinaikos conquers PAOK through Tavlaridis goal
A Stathis Tavlaridis goal has brought Panathinaikos to practically within one point from clinching a spot in next season’s Champions League qualifiers, as the Greens made it three out of thr...
Inside Sports
COMMENTARY
Zenobia, Barbara, Christine and the general’s daughter
ATHENS – Lovely Palmyra has fallen to the zombie horde and its people are being slaughtered as the ancient city awaits its fate. It is Friday, May 22, 2015, and from my window I see the end-...
INTERVIEW
The eurozone’s ‘ambiguous’ architecture
“That’s not something you’re supposed to say in public, right?” In his humble way, Thomas Sargent, Nobel Prize winner in Economics, tries to avoid the question posed to him by Kathimerini re...
Inside Comment
SPONSORED LINK: FinanzNachrichten.de
SPONSORED LINK: BestPrice.gr
 RECENT NEWS
1. Wemmer pens three-year deal with Panathinaikos
2. Greek credit contraction amounted to 2.4 pct in April
3. Export-oriented firms benefit from euro rate
4. VAT hike would put several Athens hotels at risk
5. ATHEX: May ends with a rise of 0.3 pct
6. Greece, creditors seek breakthrough as clock runs down
more news
Today
This Week
1. Greece creditors say no deal near as G-7 frustration vented
2. Only Greece can end its miserable 'Groundhog Day'
3. Next Greek aid program isn’t on table yet, says Moscovici
4. 12 Russians injured in lightning strike at ruins on Crete
5. Some blame EU Commission for Greek obstinacy in debt talks
6. The eurozone’s ‘ambiguous’ architecture
Today
This Week
1. Hotel contracts with a ‘Greek default clause’
2. Some 300 mln left banks on Tuesday
3. Neither Grexit nor a dual currency will solve Greece’s problems
4. No more 'quick and dirty' fixes for Greece
5. Romantic notions meet reality
6. Endless confusion and worry
   Find us ...
  ... on
Twitter
     ... on Facebook   
About us  |  Subscriptions  |  Advertising  |  Contact us  |  Athens Plus  |  RSS  |   
Copyright © 2015, H KAΘHMEPINH All Rights Reserved.